Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension (FUTURE 3)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Actelion
ClinicalTrials.gov Identifier:
NCT01223352
First received: October 12, 2010
Last updated: June 2, 2016
Last verified: June 2016

October 12, 2010
June 2, 2016
March 2011
April 2013   (final data collection date for primary outcome measure)
Daily exposure [AUC(0-24c)] to bosentan [ Time Frame: At Week 4, after at least 2 weeks of stable study drug treatment ] [ Designated as safety issue: No ]

Daily exposure was measured by the area under the plasma concentration-time curve over a period of 24 hours [AUC(0-24)].

Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 12 hours or up to 8 hours post-dose for the b.i.d and t.i.d. dosing regimen, respectively. AUC(0-24) was calculated as a multiple of AUCtau (i.e., the AUC over a dosing interval): AUCtau x 2 for the b.i.d. dosing regimen and AUCtau x 3 for the t.i.d. regimen. As the smallest dose unit was 8 mg (1/4 tablet), it was not possible to achieve the exact target dose of 2 mg/kg. Therefore, AUC(0-24) was corrected to 2 mg/kg (target dose) [AUC(0-24c)].

Daily exposure to bosentan (AUC over 24 hours) [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
Daily exposure to bosentan, i.e., AUC over a period of 24 h (AUC0-24h), and calculated as a multiple of the exposure over a dosing interval (AUCτ), 3 × AUCτ and 2 × AUCτ for three times and two times daily dosing, respectively.
Complete list of historical versions of study NCT01223352 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
  • Maximum plasma concentration [Cmaxc] of bosentan [ Time Frame: At Week 4, after at least 2 weeks of stable study drug treatment ] [ Designated as safety issue: No ]

    Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 12 hours or up to 8 hours post-dose for the b.i.d and t.i.d. dosing regimen, respectively.

    The peak plasma concentration (Cmax) of bosentan was directly obtained from the measured plasma concentrations and was dose-corrected to the target dose of 2 mg/kg (Cmaxc).

  • Time to reach Cmax [tmax] of bosentan [ Time Frame: At Week 4, after at least 2 weeks of stable study drug treatment ] [ Designated as safety issue: No ]

    Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 12 hours or up to 8 hours post-dose for the b.i.d and t.i.d. dosing regimen, respectively.

    tmax was obtained directly from the measured plasma concentrations.

  • Daily exposure [AUC(0-24c)] to bosentan metabolites (Ro 478634, Ro 485033, Ro 641056) [ Time Frame: At Week 4, after at least 2 weeks of stable study drug treatment. ] [ Designated as safety issue: No ]
    Concentrations of the metabolites were measured directly in blood samples collected prior to study drug administration and up to 12 hours or up to 8 hours post-dose for the b.i.d and t.i.d. dosing regimen, respectively. Daily exposure to the metabolites corresponds to the area under the concentration-time curve [AUC(0-24)] of the corresponding metabolite over a period of 24 hours, and was calculated in the same manner as the primary endpoint. AUC(0-24c) was corrected to 2 mg/kg (target dose) [AUC(0-24c)].
  • Change from baseline in WHO functional class at end of study [ Time Frame: Baseline and end of study ] [ Designated as safety issue: No ]
    Number of patients with improvement, worsening or no change in WHO functional class at end of study compared to baseline.
  • Change from baseline in Global clincial impression scale (GCIS) at end of study [ Time Frame: Baseline and end of study ] [ Designated as safety issue: No ]

    The GCIS is an assessment tool to rate the patient's current overall clinical condition ("Very Good", "Good", "Neither Good or Bad", "Bad" and "Very Bad"). The assessment was performed both by the physician and the parents

    / legal representatives independently. Number of patients with clinical condition (as measured by the GCIS) considered as worsened, improved or unchanged are reported here

  • Number of patients with treatment-emergent liver function abnormalities [ Time Frame: From baseline up to 7 days after end of treatment ] [ Designated as safety issue: Yes ]
    Number of patients with increase in alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) above 3 x ULN (upper limit of normal). The worst post-baseline value was considered.
  • Number of patients with treatment-emergent hemoglobin abnormalities [ Time Frame: From baseline up to 7 days after end of treatment ] [ Designated as safety issue: Yes ]
    Number of patients with marked hemoglobin decreases. The worst post-baseline value was considered.
Not Provided
 
Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension
An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension
The primary objective of AC-052-373 was to assess the pharmacokinetic (PK) profile of two dosing regimens of the pediatric formulation of bosentan in children with pulmonary arterial hypertension (PAH) <12 years of age.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Pulmonary Arterial Hypertension
Drug: bosentan
32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.
Other Names:
  • Tracleer
  • ACT-050088
  • Experimental: Bosentan 2 mg/Kg t.i.d.
    2 mg/kg bosentan administered three times a day (morning, afternoon, evening) for a planned duration of 24 weeks
    Intervention: Drug: bosentan
  • Experimental: Bosentan 2 mg/Kg b.i.d.
    2 mg/kg bosentan administered twice daily (morning and evening) for a planned duration of 24 weeks
    Intervention: Drug: bosentan
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
64
August 2013
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. PAH diagnosis confirmed with right heart catheterization (RHC):

    • Idiopathic or heritable PAH, or
    • Associated PAH persisting after complete repair of a congenital heart defect (PAH has to be persistent for at least 6 months after surgery) or
    • PAH-CHD associated with systemic-to-pulmonary shunts (after global amendment dated 09 May 2012)
  2. WHO functional Class I, II or III
  3. Male or female ≥ 3 months and < 12 years of age (maximum age at randomization is 11.5 years)
  4. Body weight ≥ 3.5 kg
  5. Peripheral oxygen saturation (SpO2) ≥ 88% (at rest, on room air)
  6. Baseline PAH-therapy (Calcium channel blocker, bosentan, prostanoid, PDE-5 inhibitor) if present, has to be stable for at least 3 months prior to screening. During the study, all background treatments should remain stable
  7. Signed informed consent by the parents or legal representatives

Exclusion Criteria:

  1. PAH etiologies other than listed above
  2. Non-stable disease status
  3. Need or plan to wean patient from intravenous epoprostenol or intravenous or inhaled iloprost
  4. Systolic blood pressure < 80% of the lower limit of normal range
  5. AST and/or ALT values > 1.5 times the upper limit of normal range.
  6. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C
  7. Hemoglobin and/or hematocrit levels < 75% of the lower limit of normal range.
  8. Known intolerance or hypersensitivity to bosentan or any of the excipients of the dispersible Tracleer tablet
  9. Treatment with forbidden medication within 2 weeks or at least 5 times the half-life prior to randomization, whichever is the longest:

    • Glibenclamide (glyburide)
    • Cyclosporin A
    • Sirolimus
    • Tacrolimus
    • Fluconazole
    • Rifampicin (rifampin)
    • Ritonavir
    • Co-administration of CYP2C9 inhibitors (e.g., amiodarone, voriconazole) and moderate/strong CYP3A4 inhibitors (e.g., amprenavir, erythromycin, ketoconazole, diltiazem, itraconazole)
    • Endothelin receptor antagonists (ERAs) other than bosentan
  10. Treatment with another investigational drug within 1 month prior to randomization or planned treatment
Both
3 Months to 12 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Belarus,   China,   Czech Republic,   France,   Germany,   Hungary,   India,   Israel,   Italy,   Mexico,   Netherlands,   Poland,   Russian Federation,   Serbia,   South Africa,   Spain,   Ukraine
 
NCT01223352
AC-052-373
Yes
Not Provided
Not Provided
Actelion
Actelion
Not Provided
Investigator: Andjela Kusic-Pajic, MD Actelion
Actelion
June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP